Loading stock data…
Certara (CERT)
$6.36+0.52 (+8.90%)
Market ClosedLast close Jun 29
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Certara, Inc. in the Healthcare sector is trading at $6.36 with a market capitalization of $930M. Wall Street consensus targets $7.48 (10 analysts), implying a +17.6% move over the next 12 months. The stock is currently 54% below its 52-week high of $13.88, remaining 22.0% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 70 is overbought against a weak tape. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +17.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 70 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $106.92M↑ | $103.65M↓ | $104.62M | $104.57M↓ | $106.00M |
| Gross Profit | $65.30M↑ | $64.48M↓ | $64.90M↑ | $63.85M↓ | $64.48M |
| Operating Income | -$4.30M↓ | $836,000↓ | $3.00M↓ | $9.55M↑ | $7.62M |
| Net Income | -$8.76M↓ | -$5.89M↓ | $1.52M↑ | -$1.97M↓ | $4.74M |
Peer Comparison
JNJUNHPFE
Fundamentals
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Mi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$930.26M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.48%
Volume
Today's trading volume
4.64M
Recent News
Will CONMED’s New CFO Shift CNMD’s Financial Playbook Or Deepen Its Existing Strategy?
On June 17, 2026, CONMED Corporation announced that John E. Gallagher will become Executive Vice President, Chief Financial Officer, and principal financial and accounting officer from July 15, 2026, succeeding Todd Garner, who will remain in an advisory role until November 2, 2026. Gallagher’s nearly three decades of finance leadership across healthcare and industrial companies, including senior roles at Certara, Cue Health, and Becton Dickinson, signals a refreshed approach to CONMED’s...
Certara (CERT) Stock Sees Fair Value Edges Lower As Analysts Trim Targets
Certara’s updated analyst model now carries a slightly lower fair value price target of US$7.48, compared with the prior US$7.62, reflecting only a modest adjustment. This small move aligns with recent Street commentary, where bullish analysts highlight profitable operations and long term growth drivers, while more cautious voices trim targets as they reassess valuation multiples and execution timelines. As you read on, you will see how these shifting views fit together and how to keep track...
Certara Outlines AI Push, Cost Cuts and New Growth Engines at Jefferies Conference
Certara (NASDAQ:CERT) executives outlined the company’s strategic realignment, artificial intelligence initiatives and cost priorities during a discussion at Jefferies’ 2026 Global Healthcare Conference, with newly appointed Chief Executive Officer Jon Resnick saying the company is focused on creati
How Certara (CERT) Investors Can Read The Quiet Shift In The Valuation Story
The latest update for Certara keeps the existing price target unchanged, with no revisions to the prior figure. With no new analyst commentary alongside this decision, the steady target reflects the current published view rather than a fresh take on the stock. Read on to see how to track this kind of quiet shift in the narrative and what to watch for as new information emerges. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value...
Is Now An Opportune Moment To Examine Certara, Inc. (NASDAQ:CERT)?
Certara, Inc. ( NASDAQ:CERT ), might not be a large cap stock, but it received a lot of attention from a substantial...